Download het volledig rapport (302 p.) - KCE

KCE reports vol. 6A Prenatale zorg 163
Study Ref Population Intervention Outcomes Results Comments Study
type
centers until 1 year of
age to confirm
or exclude
congenital
toxoplasmosis
NPV (%) 87 76 94 91 88 79 84 83
What are the available interventions for managing women who are infected with toxoplasmosis?
Study Ref Population Intervention Outcomes Results Comments Study
Peyron
et al.,
2002
Wallon
et al.,
1999
Bader et
al., 1997
4
[476]
4
[477]
4
[479]
0 RCTs Treatment vs. no treatment of
toxoplasmosis in pregnancy to reduce the
risk of congenital toxoplasma infection
9 studies
identified
Treatment (spiramycin alone,
pyrimethamine-sulphonamides, or a
combination of the two) vs. no treatment of
toxoplasmosis in pregnancy to reduce the
risk of congenital toxoplasma infection
N/A Decision analysis to compare no testing for
congenital toxoplasmosis, targeted screening
in cases of abnormalities noted on
ultrasound and universal serological
screening of pregnant women followed by
amniocentesis to diagnose fetal infection in
Congenital
infection and
clinical congenital
infection
Congenital
toxoplasmosis
infection vs. no
infection
Pregnancy loss
avoided
EL
No RCTs identified
type
SR 1a
5 studies showed effectiveness of treatment
(p < 0.001):
22% vs. 52%
13% vs. 100%
21% vs. 47%
0% vs. 100%
4% vs. 83%
4 showed treatment was not effective:
5% vs. 17%
0% vs. 10%
10% vs. 10%
24% vs. 21%
By medical treatment: universal screening
reduced the number of cases of congenital
toxoplasmosis at the ÂcostÊ of 18.5 additional
pregnancy losses for each case avoided
By pregnancy termination: additional 12.1
EL
SR 2b
ME 3